Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00703820 · ClinicalTrials.gov registry record · Phase 3
Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia
A Phase 3 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 324
- Enrollment target
NCT00703820 is a Phase 3 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 324 participants.
The verdict
NCT00703820, a Phase 3 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 324 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and attempt to optimize outcome through the use of MRD-adapted therapy and further improvements in supportive care.
Interventions
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Daunorubicin
- DEVICE CliniMACS
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 324 participants |
| Start Date | 2008-08-04 |
| Est. Completion | 2020-08-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00703820
The ClinicalTrials.gov registry entry for NCT00703820 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 324 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Etoposide is the first listed.
NCT00703820 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00703820 about?
NCT00703820 is a clinical study titled "Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia". The purpose of this study is to assess the feasibility and efficacy of a novel form of therapy-haploidentical NK cell transplantation-in patients with standard-risk AML. In addition, we will investigate the efficacy of clofarabine + cytarabine (Clo/AraC) in newly diagnosed patients with AML and atte...
What is the current status of trial NCT00703820?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 324 participants. The study started on 2008-08-04. Estimated completion is 2020-08-14.
What interventions are being tested in trial NCT00703820?
The interventions under investigation include: Etoposide (DRUG), Cytarabine (DRUG), Daunorubicin (DRUG), CliniMACS (DEVICE), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00703820?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.